특허실시__글9건

  1. 2019.06.04 국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMINATION 영문조항 샘플
  2. 2019.06.04 국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASSISTANCE 조항 샘플
  3. 2019.05.31 특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTIES 샘플
  4. 2019.05.31 특허 전용실시권 허여계약의 특약사항 등록 여부와 특약위반 실시행위의 특허침해책임 관계 – 특약사항 미등록 및 전용실시권자의 특약위반 실시행위 - 특허권침해책임 불인정: 대법원 2013...
  5. 2019.05.29 특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실무적 포인트 몇 가지
  6. 2019.05.28 특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플
  7. 2019.05.20 기술이전, 특허 라이선스 계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTIES 계약조항 샘플
  8. 2016.04.27 기술사용계약의 적용범위 해석 + 계약대상 특허기술 범위 + 계약위반 책임여부 판단: 서울고등법원 2016. 3. 31. 선고 2015나2055753 판결
  9. 2016.02.25 인터넷뱅킹 등에 사용되는 보안소프트웨어 플러그인 통합설치 프로그램 관련 영업비밀 침해 사건 – 서울중앙지방법원 2016. 1. 15. 선고 2014가합563704 판결

 

 

17. TERM AND TERMINATION. 

17.1 Termination Prior to the Closing Date.

This Agreement may be terminated at any time prior to the Closing Date (with respect to Sections 17.1(b) and 17.1(c) below, by written notice by the terminating Party to the other Party): (a) by mutual written agreement of the Parties;

 

(b) by Licensor or Licensee, if a court of competent jurisdiction or other Governmental Authority shall have issued a non-appealable final order, decree or ruling or taken any other non-appealable final action, in each case, having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement; provided, however, that the right to terminate this Agreement under this Section 17.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the primary cause of, or materially contributed to, such action; or

 

(c) by Licensee, if Licensor has breached any representation, warranty, covenant or agreement of Licensor set forth in this Agreement which (i) would result in a failure of a condition set forth in Section 13.2 and (ii) is not cured within thirty (30) calendar days after written notice thereof.   

 

17.2 Term.

Except as provided in Section 17.1, this Agreement shall continue until the date of expiration of the Royalty Term, unless earlier terminated in accordance with this Article 17 (the “Term”).  

 

17.3 Termination of the Agreement After the Closing Date.  

 

(a) Termination by Licensee. 

Licensee may terminate this Agreement in its entirety or in part (including, for example, on a country-by-country basis) for any reason (a) upon at least ninety (90) days prior written notice to Licensor if such notice is delivered prior to the First Commercial Sale of a Licensed Product anywhere in the Territory or (b) upon at least one hundred eighty (180) days prior written notice to Licensor if such notice is delivered after the First Commercial Sale of a Licensed Product anywhere in the Territory.  In the event of any significant adverse clinical events or the termination of a Clinical Trial for safety reasons and Licensee terminates this Agreement under this Section 17.3(a), the foregoing notice periods in clauses (a) and (b) shall be reduced to forty-five (45) days and ninety (90) days, respectively.

 

(b) Termination for Material Breach. 

If either Party believes the other is in material breach of its obligations under this Agreement, it may give notice of such breach to the other Party, which Party shall have sixty (60) days in which to remedy such breach, or thirty (30) days in the case of material breach of any payment obligation hereunder.

 

Such sixty (60) day period shall be extended in the case of a breach not capable of being remedied in such sixty (60) day period so long as the breaching Party uses diligent efforts to remedy such breach and is pursuing a course of action that, if successful, will effect such a remedy; provided, however, that such cure period shall not be extended more than sixty (60) additional days. 

 

If such alleged breach is not remedied or is not capable of being remedied within the period set forth above, the non-breaching Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement upon written notice to the other Party.  In the event of a dispute regarding any payments due and owing hereunder, all undisputed amounts shall be paid when due and the balance, if any, shall be paid promptly after settlement of the dispute including any accrued interest thereon.  

 

(c) Consequences of Termination. 

In the event that either Party terminates this Agreement, then as of the effective date of such termination, the following terms and conditions shall apply:

 

(i) Termination by Licensor for Licensee’s Material Breach. 

In the event of termination of this Agreement by Licensor pursuant to Section 17.3(b) for Licensee’s uncured material breach, and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:

 

(A) all licenses and rights granted by either Party under this Agreement shall terminate with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c) which shall become perpetual, worldwide and fully paid; 

 

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination; 

 

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination; 

 

(D) Licensee shall transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory. 

 

(ii) Termination by Licensee. 

Subject to Section 17.3(c)(ii)(E), in the event of termination of this Agreement by Licensee pursuant to Section 17.3(a), and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:  

 

(A) all licenses and rights granted by either Party under this Agreement shall terminate, with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c), which shall become worldwide, subject to Licensor’s obligations under subsection (E) below;  

 

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination; 

 

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination;  

 

(D) Licensee shall, upon receipt of reasonable consideration from Licensor based on an actual cost basis, transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory; and 

 

(E) in partial consideration for (A) Licensee’s costs of obtaining and maintaining such Regulatory Approvals and Commercializing Licensed Products in the Territory prior to the date of such termination, and/or (B) subject to Section 19.1, the license granted under the Licensee Inventions, Licensor shall pay to Licensee following the effective date of such termination, on a product-by-product and country-by-country basis, a commercially reasonable royalty to be negotiated in good faith by the Parties, on all sales by Licensor, its Affiliates and Sublicensees, of products that would have been Licensed Products, had they been sold by Licensee prior to the effective date of such termination. 

 

(iii) Termination by Licensee for Licensor’s Material Breach.  

In the event that Licensee has the right to terminate this Agreement for Licensor’s uncured material breach pursuant to Section 17.3(b), Licensee may terminate this Agreement or, in lieu of such termination, by written notice to Licensor after a determination that such breach was a material breach and was not cured before the expiration of the cure period set forth in Section 17.3(b), elect to retain all of the rights and licenses granted to Licensee hereunder for the remainder of the Term. Following such an election by Licensee:

 

(A) Licensee may request that damages be awarded to Licensee for Licensor’s uncured material breach by final and binding arbitration conducted in accordance with Section 19.12. In determining whether damages should be awarded to Licensee, the arbitrators shall consider the nature of Licensor’s uncured material breach and the impact of such uncured material breach on Licensee and the transactions contemplated by this Agreement. 

 

In the event that such final and binding arbitration determines that Licensee should be awarded damages, Licensee shall be entitled to deduct the amount of such damages from milestone and royalty payments to be paid to Licensor under Sections 8.2 and 8.3;

 

(B) the limitations applicable to Licensor’s activities as set forth in Sections 2.3(a) and 2.4 shall continue to apply; and

 

(C) the license granted by Licensee to Licensor under Section 9.2(c) shall terminate.    

 

17.4 Surviving Obligations. 

Upon termination of this Agreement, the Parties shall remain obligated to make all payments which have accrued under this Agreement prior to the date of termination, when and as they become due and payable.  In addition, the provisions in Articles 1, 9, 10, 14, 15, 16, 18 and 19, and Sections 2.6, 5.2, 5.7, 7.6, 8.3(h), 8.7 (with respect to payment accruing prior to the effective date of termination), 8.8, 8.9, 17.3(c), 17.4 and 17.5 of this Agreement shall survive termination of this Agreement for any reason.  

 

17.5 Accrued Rights. 

Termination or expiration of this Agreement shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement.  Termination by a Party shall not be an exclusive remedy and all other remedies will be available to the terminating Party, in equity and at law.

 

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMIN

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 4. 13:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

ARTICLE 2 - TECHNICAL ASSISTANCE

2.1   TECHNICAL DOCUMENTATION

           (a) Licensor shall furnish to Licensee, in accordance with the time schedule to be agreed upon between the Parties, one (1) set of hard copies of the Technical Documentation. If Licensee discovers that any of the documents are missing or illegible or damaged, Licensee shall inform Licensor in writing and Licensor shall make such documents available for Licensee within twenty (20) days of receiving such notice.

                                                             

           (b) The foregoing Technical Documentation to be furnished under paragraph 2.1 (a) above shall be delivered to Licensee and shall be the latest version as of the time it is delivered or sent.

 

           (c) Licensee shall pay Licensor for any additional copies of the Technical Documentation requested by Licensee at the rates agreed upon in writing by both Parties prior to sending.

 

           (d) Nothing in this Agreement shall be construed to require that Licensor furnish Licensee with any technical information on any products other than Licensed Product or any technical information which may not be furnished because of a government contract, act, regulation or restriction or the proprietary interest of a third party.

 

           (e) Errors in Technical Documentation. Each Party shall promptly advise the other of any significant error it may discover in the Technical Documentation. In that event, Licensor shall correct any error in the Technical Documentation and shall furnish such corrected Technical Documentation to Licensee without charge.

 

(f) Strict Compliance with Technical Documentation. In order to maintain the quality of the Licensed Products manufactured and assembled by Licensee pursuant to this Agreement, Licensee shall manufacture and/or assemble the Licensed Products in strict accordance with the standards and specifications stated in the Technical Documentation provided by Licensor and as otherwise specified by Licensor. Licensee shall exercise the utmost care in the selection of the materials and parts to be used and incorporated into the Licensed Products.

 

2.2      ASSISTANCE BY LICENSOR

Licensor shall provide reasonable assistance in the use of the Technical Documentation to the extent such assistance is reasonably necessary for Licensee to make use of the Technical Documentation to manufacture the Licensed Product. Such assistance may include, but will not be limited to, technical assistance, training, testing and limited application engineering services.

 

- 라이센서의 조력의무를 선언적으로 규정한 조항임. 제조에 필요한 기술정보 활용을 가능케 하도록 조력의무를 규정하고 있어 상당히 포괄적임.

- 이하에서 구제적인 비용을 규정할 경우 라이센서의 수입원이 되지만, 그렇지 않을 경우 부담조항이 될 수 있음.

                                                                           

2.3   TECHNICAL ASSISTANCE

      (a) At the request of Licensee, Licensor shall, at times agreed upon by the Parties, dispatch its engineers to Licensee to provide technical assistance on matters concerning the use of the Technical Documentation during the Technical Cooperation Period. All costs and expenses of such Licensor's personnel dispatched to Licensee shall be borne, or reimbursed to Licensor, by Licensee and shall include:

            (i)   round trip economic air fare between Korea and China;

            (ii)  suitable accommodations, meals, traveling and transportation expenses in China and other reasonable charges in connection with the performance of their duties hereunder;

            (iii) wage and daily allowance, payable to Licensor, on its demand, amounting to U$500 per Man Day for Licensor's personnel;

 

      (b) Licensee shall take appropriate steps necessary to protect and ensure the safety of Licensor's personnel and their property, including without limitation, against war, war-like operation, terror, revolution, civil commotion, catastrophe and acts of public enemies. Licensor reserves the right to  instruct any or all of its dispatched personnel to return to Korea, or such other place as it may designate, at Licensee's expense  when, in Licensor's sole judgment , one of the above-mentioned situations arises which may endanger the safety and well-being of such personnel.

- 기술자 파견에 따른 안전보장은 실시자 부담임

 

      (c) Licensee is responsible for obtaining any permits or authorizations required for Licensor's personnel to enter China to provide services hereunder, and to bring any related materials required by Licensor.

- 기술자 파견에 따른 출입국 보장은 실시자 부담

 

    (d) The number of such personnel, the period of their stay at Licensee's plant and other terms and conditions not set forth herein shall be agreed upon between the Parties on a case by case basis.

 

2.4   TRAINING

At the request of Licensee, Licensor will, during the Technical Cooperation Period, provide training on the use of the Technical Documentation for Licensee's employees (the "Trainees") at Licensor's place or other places designated by Licensor, subject to the following terms and conditions:

      (i) Licensor and Licensee shall agree on the most efficient training program for the Trainees;

      (ii) Licensee shall bear all the cost and expenses relating to the Trainees, including but not limited to their salaries, round trip airfare between China and Korea, lodgings and meals of Trainees in Korea, transportation and insurance;

      (iii) Licensor shall provide working lunches for the trainees during working days and transportation for the trainees between dormitory and training site.

      (iv) Licensee shall pay to Licensor as training fee, payable upon demand, US$300 per Trainee per day, as the compensation of training services provided by Licensor;

      (v) Licensee shall instruct the Trainees to observe and abide by all rules and regulations of Licensor and the laws of Korea during their training period;

      (vi) All Trainees shall be insured at the expense of Licensee by an internationally recognized accident compensation insurance during the entire training period between their departure from and return to China;

      (vii) Licensee shall indemnify and hold harmless Licensor against any loss, damage, claim, liabilities, cost or expense arising out of any act of a Trainee or any injury or death of the Trainee or any damage to his/her property.

 

2.5   SUPPORT OF TESTS

Pursuant to the terms of a purchase order, sale agreement or other document to be separately agreed by the Parties or Licensee and Delphi, Licensor will support the necessary manufacturing Part Production Approval Process validation tests for the Licensed Products.

 

2.6   SAMPLE TEST AND VERIFICATION

Before distribution and sale of any of the Licensed Product manufactured or assembled hereunder, Licensee shall submit, at its expense, samples of the Licensed Product for approval by Licensor. Licensor shall promptly conduct appropriate tests on such samples and advise Licensee of the results thereof. The costs of any tests on the samples shall be responsibility of Licensee, and Licensor shall advise Licensee of the test fees in advance.

 

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASS

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 6. 4. 08:47
Trackback 0 : Comment 0

댓글을 달아 주세요


11. REPRESENTATIONS AND WARRANTIES.

11.1 The Parties ’Representations and Warranties.

Each Party hereby represents, warrants and covenants to the other Party, as of the Effective Date (or as of the Closing Date in the case of Section 11.1(h)), that:

(a) such Party (i) is a corporation duly organized and validly existing under the laws of its jurisdiction of organization, and (ii) has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement;

 

(b) such Party has sufficient legal and/or beneficial title under its intellectual property rights necessary for the purposes contemplated under this Agreement and to grant the licenses contained in this Agreement;

 

(c) such Party is not aware of any pending or threatened litigation, nor has it received any notice of claim, alleging that it has violated or would violate, through the manufacture, import and/or sale of Licensed Products hereunder, or by conducting its obligations as currently proposed under this Agreement, any intellectual property or other rights of any Third Party;

 

(d) to such Party’s knowledge, all of its employees, officers, independent contractors, consultants and agents have executed agreements requiring assignment to such Party of all inventions made during the course of and as a result of their association with such Party and obligating the individual to maintain as confidential the Confidential Information of such Party;

 

(e) such Party has the power, authority and legal right, and is free to enter into this Agreement and, in so doing, will not violate any other agreement to which such Party is a party as of the Effective Date and such Party has maintained and will maintain and keep in full force and effect all agreements and regulatory filings necessary to perform its obligations under the Agreement and, during the Term, such Party shall not enter into any agreement with a Third Party that will conflict with the rights granted to the other Party under this Agreement;

 

(f) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity;

 

(g) such Party has taken all corporate action necessary to authorize the execution, delivery and performance of this Agreement;

 

(h) such Party has obtained all consents, approvals and authorizations of all Regulatory Authorities and other Third Parties reasonably deemed necessary by such Party to be obtained in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder;

 

(i) the execution and delivery of this Agreement and the performance of such Party’s obligations hereunder: (i) do not conflict with or violate any provision of the certificate of incorporation, bylaws, limited partnership agreement or any similar instrument of such Party, as applicable, in any material way; (ii) to such Party’s knowledge, do not conflict with, violate or breach or constitute a default or require any consent under any indenture, mortgage, contract or instrument to which it is party or by which it is bound; and (iii) to such Party’s knowledge, do not conflict with, violate, or breach or constitute a default or require any consent under, any requirement of Applicable Laws or court or administrative order by which such Party is bound;

 

(j) except in connection with or related to the settlement between Licensee A and the United States Department of Justice, announced on September 1, 2010, neither such Party, nor any of such Party’s employees, officers, independent contractors, consultants or agents who will render services relating to Licensed Products: (i) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a; or (ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a. If during the Term a Party has reason to believe that it or any of its employees, officers, independent contractors, consultants or agents rendering services relating to Licensed Products: (x) is or will be debarred or convicted of a crime under 21 U.S.C. Section 335a; or (y) is or will be under indictment under said Section 335a, then such Party shall immediately notify the other Party of same in writing; and

 

(k) such Party currently has no research or development project, or agreement with any Third Party, that, in such Party’s reasonable scientific or business judgement, (i) requires or is likely to require changes to the Development Plan attached hereto as Exhibit 4.1, or (ii) is likely to interfere with such Party’s ability to enter into and perform its obligations under this Agreement.

 

11.2 Representations and Warranties of Licensor M.

Licensor M hereby represents, and warrants and covenants to Licensee A, as of the Effective Date, that:

(a) Licensor M is the sole and exclusive owner of all right, title and interest, in, to and under the Licensed Intellectual Property in the Territory;

 

(b) M is the sole and exclusive owner of all right, title and interest, in, to under the Licensed Intellectual Property necessary or useful in the Manufacture of Licensed Products;

 

(c) M has sufficient rights to grant the rights and licenses granted herein, free and clear of any security interests, claims, encumbrances or charges of any kind that would conflict in any material respect with the rights and licenses granted hereunder;

 

(d) M has not assigned or granted to any Third Party any rights under the Licensed Intellectual Property that cover Licensed Products in the Territory except as granted to independent contractors in the ordinary course of business in connection with M's research, Development and Manufacturing of Licensed Products, and consistent with the terms and intent of this Agreement;

 

(e) (i) M has not received any written notice from any Third Party asserting or alleging that any Development, Manufacturing, or Commercialization of the Licensed Products has infringed or misappropriated any Patent or intellectual property right of such Third Party, (ii) to the knowledge of M, the manufacture, use, offer for sale, sale or importation of Licensed Products in the Territory has not infringed and, as of the Effective Date, will not infringe, any Patent of any Third Party or misappropriate any technology of any Third Party, and (iii) there are no pending, and, to the knowledge of M, no threatened, adverse actions, suits, arbitrations, litigations, or proceedings of any nature, civil, criminal, regulatory or otherwise, in law or in equity, against M or any of its Affiliates alleging that the Development, Manufacture, Commercialization or other exploitation of Licensed Products has infringed any Patent, or misappropriated any intellectual property right of any Third Party;

 

(f) to Licensor M’s knowledge, the issued Patents within the M Patent Rights in the Territory are valid and enforceable;

 

(g) all applicable maintenance and renewal fees with respect to the M Patent Rights in the Territory have been paid and all documents, and certificates required to be filed for the purpose of maintaining such M Patent Rights have been filed;

 

(h) to Licensor M’s knowledge, no Third Party has asserted that any Licensed Intellectual Property is invalid or not enforceable;

 

(i) (i) other than as disclosed by M in writing to A prior to the Effective Date, none of the M Patent Rights, were developed with federal or state funding from any Governmental Authority, (ii) no Governmental Authority has any march in rights or other rights to use the Licensed Intellectual Property in the Territory, and (iii) neither the execution and delivery of this Agreement nor the performance hereof by M will result in the breach of, or give rise to, any right of termination, rescission, renegotiation or acceleration under, or trigger any other rights under, any agreement or contract to which M is a party, or to which it may be subject, that relates to the Licensed Products;

 

(j) no written communication has been received by M from any Third Party that alleges, and there is no pending litigation that alleges, that (i) any issued M Patent is invalid or unenforceable as of the Effective Date, or (ii) any patent application included in the M Patents, if issued, would be, invalid or unenforceable;

 

(k) to the knowledge of Licensor M, no Third Party (i) is infringing any M Patent Rights or has misappropriated any M Know-How, or (ii) has challenged the ownership, scope, duration, validity, enforceability, priority or right to use any M Patent Rights (including, by way of example, through the institution of or written threat of institution of interference, re-examination, review, supplemental examination, derivation proceeding, protest, opposition, nullity or similar invalidity proceeding before the U.S. Patent and Trademark Office or any analogous foreign entity) or any M Know-How;

 

(l) the Licensed Intellectual Property licensed to Licensee A hereunder constitutes all of the intellectual property rights Controlled by M that are necessary for A to Commercialize Licensed Products in the Territory;

 

(m) to Licensor M’s knowledge, M has complied in all material respects with all Applicable Laws in the prosecution and maintenance of the M Patent Rights in the Territory;

 

(n) all of Licensor M’s and its Affiliates’ employees, officers, and consultants/contractors involved in the research, Manufacture or Development of Licensed Products are and have been obligated to assign to M or such Affiliate, as the case may be, all Inventions claimed in the M Patent Rights and to maintain as confidential the Confidential Information of M or such Affiliate, as applicable; and

 

(o) all inventors of any Inventions included within the M Patent Rights and M Know-How have assigned their entire right, title, and interest in and to such Inventions and the corresponding Patents and Information to M and have been listed in the M Patent Rights as inventors.

 

KASAN_특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATI

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019. 5. 31. 16:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

1. 특허권에 대한 전용실시계약 체결, 특약사항 및 등록 상황

특허권자 회사로부터 공기정화제특허발명의 등록 특허권에 대하여 전용실시권을 설정받으면서 특허권자 회사에 대해 귀사의 승낙 없이 특허를 임의대로 사용하지 않겠다는 사전승낙 조건을 추가하였습니다. 그 후 라이센시는 특허등록원부에 전용실시권 등록을 마쳤지만, 위 계약상 제한사항을 특허등록원부에 등록하지 않았습니다.

 

2. 실시권자 라이센시의 계약상 특약조항 위반

실시권자는 특허권자의 승낙 없이 임의대로 특허권을 실시하였고, 특허권자는 전용실시권 설정 계약위반, 전용실시권 설정계약범위 외의 실시행위로 특허권침해에 해당한다고 주장하면서 실시권자 라이센시를 형사고소하였습니다.

 

3. 특허법 규정

특허법 제100(전용실시권) 특허권자는 그 특허권에 대하여 타인에게 전용실시권을 설정할 수 있다. 전용실시권을 설정받은 전용실시권자는 그 설정행위로 정한 범위에서 그 특허발명을 업으로서 실시할 권리를 독점한다.

 

특허법 101(특허권 및 전용실시권의 등록의 효력) 다음 각 호의 어느 하나에 해당하는 사항은 등록하여야만 효력이 발생한다.

1. 특허권의 이전(상속이나 그 밖의 일반승계에 의한 경우는 제외한다), 포기에 의한 소멸 또는 처분의 제한

2. 전용실시권의 설정·이전(상속이나 그 밖의 일반승계에 의한 경우는 제외한다변경·소멸(혼동에 의한 경우는 제외한다) 또는 처분의 제한

3. 특허권 또는 전용실시권을 목적으로 하는 질권의 설정·이전(상속이나 그 밖의 일반승계에 의한 경우는 제외한다변경·소멸(혼동에 의한 경우는 제외한다) 또는 처분의 제한

 

4. 법원판단 특허침해 불성립

법원은 전용실시권 설정계약상의 제한사항을 등록하지 않은 경우, 그 제한을 위반하여 특허발명을 실시한 전용실시권자에게 특허법 위반죄가 성립하지 않는다고 판결하였습니다. 법원은 실시권자의 전용실시권 설정계약을 위반한 계약상 민사책임은 인정될 수 있지만, 등록되지 않는 특약사항으로 전용실시권자의 실시권한을 제한할 수 없다는 입장에서 전용실시권자의 특허실시행위는 특허권 침해에 해당하지 않는다고 명확하게 판결하였습니다.

 

5. 대법원 2013. 1. 24. 선고 20114645 판결 요지

특허법 제101조 제1항은 다음 각 호에 해당하는 사항은 이를 등록하지 아니하면 그 효력이 발생하지 아니한다.”고 하면서, 2호에 전용실시권의 설정·이전(상속 기타 일반승계에 의한 경우를 제외한다변경·소멸(혼동에 의한 경우를 제외한다) 또는 처분의 제한을 규정하고 있다.

 

따라서 설정계약으로 전용실시권의 범위에 관하여 특별한 제한을 두고도 이를 등록하지 않으면 그 효력이 발생하지 않는 것이므로, 전용실시권자가 등록되어 있지 않은 제한을 넘어 특허발명을 실시하더라도, 특허권자에 대하여 채무불이행 책임을 지게 됨은 별론으로 하고 특허권 침해가 성립하는 것은 아니다.

 

6. 등록주의 여부에 따른 구별

대법원 판결은 전용실시권이 그 설정등록으로 발생, 소멸, 변경된다는 등록주의에 따른 것입니다. 그 기초인 전용실시권 설정계약 위반을 이유로 그 계약이 해지되었는지 여부와는 명확하게 구별하였습니다.

 

그런데, 미국 특허법과 우리나라 특허법은 전용실시권의 발생 및 소멸에 대해 다른 입장을 취하고 있습니다. 따라서, 실시권자 라이선시의 실시권 설정 계약위반 사안에 대해 특허침해 책임여부에 관해서도 서로 다른 결론에 도달할 수 있습니다. 예를 들어, 미국사안과 같이 전용실시권자의 라이선스 계약위반행위가 있더라도 유효한 전용실시권 등록이 존속하고 있는 한 licensee의 계약위반에 따른 책임은 별론으로 하더라도 적어도 특허침해는 성립하지 않습니다. 반면, 미국법원은 계약위반책임과 별개로 특허침해도 가능하다는 취지입니다.

 

KASAN_특허 전용실시권 허여계약의 특약사항 등록 여부와 특약위반 실시행위의 특허침해책임 관계 – 특약사항 미등록

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 31. 11:30
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

KASAN_특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019. 5. 29. 16:01
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

2. LICENSE GRANT. 

2.1 License Grant to A. 

Subject to the terms and conditions of this Agreement, Licensor M hereby grants to Licensee A an exclusive (even as to M and its Affiliates), royalty-bearing license, with the right to grant sublicenses through multiple tiers (subject to Section 2.2), under the M Know-How and M Patent Rights, to Develop, manufacture, use, sell, offer for sale, import, export and otherwise Commercialize Licensed Products in the Territory subject to and in accordance with the terms and conditions of this Agreement.  The foregoing license includes the right to have any of the foregoing performed pursuant to Section 2.2.

 

2.2 Sublicense and Subcontracting Rights. 

Licensee A shall require A’s Sublicensees to agree in writing to be bound by all of the applicable terms and conditions of this Agreement. A’s grant of any sublicense shall not relieve A from any of A’s obligations under this Agreement, and A shall remain jointly and severally liable for any uncured breach of a sublicense by a Sublicensee of A to the extent that such uncured breach would constitute a breach of this Agreement. A shall have the right to retain a Third Party contractor to perform any activity in connection with A’s exercise of any of its rights granted under Section 2.1, where such activity is to be performed at the direction and control and for the sole benefit of A or its Affiliates. A shall ensure that any and all activities performed by the Third Party contractor comply in all respects with the terms and conditions of this Agreement, and shall remain primarily liable for all such activities of the Third Party contractor. Such retention of the Third Party contractor is not a sublicense within the meaning of this Section 2.2 but is considered an activity of A under the license granted in Section 2.1. 

 

2.3 Certain Restrictions.  

(a) Except as otherwise expressly provided in Section 2.4, Licensor M agrees that it shall not, and will cause its Affiliates to not, offer to sell, license or otherwise provide any rights, including for example distribution rights, to Licensed Products, or under M Patent Rights or M Know How, to any Third Party if M or its relevant Affiliates, knows, or has a reason to believe (i) that such Licensed Product would be sold or transferred into the Territory; or (ii) that M Patent Rights or M Know How would be used, directly or indirectly, to manufacture, develop or commercialize a Licensed Product, or any product that would be reasonably expected to compete with a Licensed Product, or any product that would infringe at least one Valid Claim of a M Patent Right, which product, in each case, would be sold or transferred into the Territory. M agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from actions described in this Section 2.3(a). 

 

(b) Licensee A agrees that it shall not, and will cause its Affiliates to not, (i) offer to sell or otherwise provide Licensed Products to any Third Party if A or its relevant Affiliates, knows, or has reason to believe that the Licensed Product offered for sale, sold or provided to such Third Party would be, directly or indirectly, sold or transferred into North Korea or into South Korea; and (ii) use or practice under any intellectual property right licensed to it under this Agreement except as expressly permitted by this Agreement.  A agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from such actions described in Section 2.3(b)(i) and (ii).  

 

2.4 Reservation of Rights.  

(a) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to (i) Manufacture Licensed Products and supply such Licensed Products to A pursuant to the terms of the Supply Agreement, (ii) develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize the M Products anywhere in the world, (iii) subject to Section 2.5, develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize MT10 (but not any formulation thereof other than the lyophilized formulation of M’s proprietary 150kDa botulinum toxin type A product without human serum albumin) anywhere in the world either itself or through a Third Party, and (iv) develop, manufacture and use, sell, offer for sale, import, export and otherwise commercialize, under the M Know-How and M Patent Rights, any M Product that complies with cGMP (a “cGMP M Product”) anywhere in the world either by itself or through a Third Party; provided that, notwithstanding anything to the contrary, if M develops any cGMP M Product, M shall not, and shall not license, authorize or otherwise permit any Third Party to, at any time during the Term, (A) file for Regulatory Approval of a cGMP M Product in any country in the Territory as a “biosimilar” or a “follow-on biologic” or a “subsequent entry biologic” or other comparable term under applicable regulatory regimes in such country, or (B) market, promote, sell, offer for sale, import, export or otherwise commercialize a cGMP M Product anywhere in the United States or anywhere in Canada or in any Member country of the European Union.

 

(b) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to use, sell, offer for sale, import, export and otherwise Commercialize MT10 in Japan, but only in Japan and in no other country in the Territory; provided that (i) M and A shall be co-exclusive with respect to such activities with respect to MT10 in Japan, (ii) M may not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise, and (iii) M shall have no right to grant sublicense rights to any Third Party with respect to MT10 in Japan but shall have the right to grant sublicense rights to an Affiliate of M in Japan; provided that, with respect to any such Affiliate, (A) M has a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate and (B) no competitor of A has any control or equity interest in such Affiliate, in both (A) and (B), as of the effective date of such sublicense and remains so throughout the term of the sublicense. For purposes of clarification, in the event that M grants a sublicense to an Affiliate of M pursuant to (iii) above and, at any time after the effective date of the sublicense, either (1) M does not have a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate or (2) a competitor of A acquires any control or equity interest in such Affiliate whether by, for example, investment, acquisition or merger, M agrees that such sublicense shall terminate. In connection with such M retained right, A agrees that it shall not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise.   

 

2.5 Right of First Refusal. 

If Licensor M wishes to seek Regulatory Approval for and Commercialize MT10 with any Third Party, including without limitation by way of license, partnership, joint venture, collaboration, distribution or other similar relationship, Licensee A shall have a right of first refusal to obtain an exclusive (even as to M and its Affiliates) right and license to MT10 in the Territory.  M shall present to A, prior to any discussion with any Third Party, a complete data package summarizing all available data with respect to the MT10 program and a good faith proposal of terms and conditions for A to obtain an exclusive right and license to MT10, and the Parties shall comply with the procedure set forth in this Section 2.5. The Parties shall proceed promptly to negotiate the terms of a definitive agreement, and shall use commercially reasonable efforts to do so within one hundred and twenty (120) days after initiating such negotiations. In the event that A and M have not agreed upon the material terms and conditions pursuant to which A would receive such a right and license to MT10 within such one hundred and twenty (120) day period after the initiation of discussions (the “ROFR Period”), M shall be free to discuss terms and conditions for the grant of rights and license with respect to MT10 with any Third Party; provided that the terms and conditions offered to the Third Party are not more favourable to such Third Party than those that have been offered to A.  If M has not entered into a definitive written agreement with a Third Party with respect to MT10 within nine (9) months after the later of (i) the date of the expiration of the ROFR Period and (ii) the date of the termination of the negotiations between M and A regarding the terms and conditions of a license to MT10, then M shall not offer to any Third Party any rights to MT10 unless and until M has first offered A a further right of first refusal to obtain such a license, which further right of first refusal shall operate in accordance with the terms of this Section 2.5. 

 

2.6 No Implied Rights or Licenses. 

Licensor M grants no additional rights or licenses in or to any Patent or other intellectual property right, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this Agreement.

 

KASAN_특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플.p

 

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 28. 13:04
Trackback 0 : Comment 0

댓글을 달아 주세요


 

10. REPRESENTATIONS, WARRANTIES, AND COVENANTS. 

 

10.1 Mutual Representations and Warranties. Licensor and Licensee (each, a “Representing Party”) each hereby represents and warrants to each other, as of the Effective Date and except as otherwise set forth in Schedule 10.2 (in the case of Licensor) and Schedule 10.3 (the case of Licensee), that:  

 

(a) such Representing Party is a corporation or limited liability company, as applicable, duly organized and subsisting under the laws of its jurisdiction of organization; 

 

(b) such Representing Party has the power, authority, and legal right, and is free, to enter into this Agreement on behalf of itself and its Affiliates and to perform its respective obligations hereunder and to cause its Affiliates to perform their respective obligations hereunder; 

 

(c) such Representing Party has the power, authority, and legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement; 

 

(d) this Agreement constitutes a legal, valid, and binding obligation of such Representing Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity; 

 

(e) the execution and delivery of this Agreement and the performance of such Representing Party’s and its Affiliates’ obligations hereunder (i) have been duly authorized and approved by all necessary action by such Representing Party, and all necessary consents, approvals, and authorizations of all Regulatory Authorities and other Third Parties required to be obtained by such Representing Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained; (ii) do not conflict with or violate any requirement of Applicable Laws or any provision of the articles of incorporation, bylaws, limited partnership agreement, or any similar instrument of such Representing Party, as applicable, in any material way; and (iii) do not, and will not, conflict with or otherwise interfere with in such a manner as to result in a violation, breach, or default under or require any consent that has not been obtained under any contract between such Representing Party and any Third Party; 

 

(f) there are no, and shall be no, liens, conveyances, mortgages, assignments, encumbrances, or other agreements that would prevent or impair such Representing Party’s or any of its Affiliates’ full and complete exercise of the terms and conditions of the Agreement; 

 

(g) such Representing Party and its Affiliates shall at all times comply with all Applicable Laws relating or pertaining to their obligations under the Agreement; 

 

(h) with respect to the services provided hereunder to the other Party, its Affiliates, and their respective employees, officers, contractors and agents who perform such services have the experience, capability, and resources to efficiently and skillfully perform the services, and shall perform, where applicable, all such services in a professional and workmanlike manner and in accordance with the generally accepted then-current standards, forms, procedures, and techniques established from time to time by the industry; 

 

(i) all of such Representing Party’s employees, officers, contractors, and consultants have executed agreements requiring assignment to such Representing Party of all inventions created by such persons in the course of their employment by such Representing Party and obligating each such employee, officer, contractor, and consultant to maintain and safeguard the confidentiality of (i) any information that is confidential to such Representing Party or (ii) any information that is confidential to any other Person and that such Representing Party is obligated to maintain and safeguard as confidential; and

 

(j) neither such Representing Party, nor any of its employees, officers, subcontractors, or consultants who have rendered or will render services relating to the Product: (i) has ever been debarred or is subject or debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a or (ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a. 

 

10.2 Additional Representations, Warranties, and Covenants of Licensor. Licensor hereby represents, warrants, and covenants to Licensee, as of the Effective Date and except as otherwise set forth in Schedule 10.2, that: 

 

(a) Licensor is entitled to grant the rights and licenses purported to be granted to Licensee under this Agreement, and to assign the rights purported to be assigned to Licensee under this Agreement, and is not currently bound by any agreement with any Third Party, or by any outstanding order, judgment, or decree of any court or administrative agency, that restricts it from granting to Licensee the rights, licenses and sublicenses purported to be so granted in this Agreement; 

 

(b) Licensor is the sole and exclusive owner of all right, title, and interest, in, to, and under the Licensed Rights and has the right under the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights to grant the sublicenses thereunder in accordance with Section 2.2; 

 

(c) the Licensed Rights are free and clear of any liens, charges, encumbrances, or judgments, and Licensor has sufficient rights to grant the licenses and rights purported to be granted herein, free and clear of any security interests, claims, encumbrances, or charges of any kind; 

 

(d) Licensor has not granted, and will not grant during the term of this Agreement, any right, option, license, or interest in or to any of the Licensed Rights that is in conflict with the rights assigned or granted to Licensee under this Agreement; 

 

(e) there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any nature, judgment, decree, decision, injunction, writ, or order pending, or to Licensor’s knowledge threatened by, against or involving Licensor, regarding the Licensed Rights, whether at law or in equity, before or by any Third Party, and Licensor has not received any written communications alleging that it has violated, through the manufacture, Development, import, or other exploitation of the Product, any intellectual property rights of any Third Party; 

 

(f) to Licensor’s knowledge: 

(i) the patents in the issued Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent Rights are valid and enforceable; and

(ii) no Third Party has asserted that any of the Licensed Rights or the Sublicensed Rights is invalid or unenforceable; 

 

(g) all applications, registrations, maintenance and renewal fees due in respect of any of the Licensed Serenity Patent Rights and, to Licensor’s knowledge, the Licensed Reprise Patent Rights and the Licensed CPEX Patent Rights, have been paid and all documents and certificates required to be filed with the relevant agencies for the purpose of maintaining such Licensed Serenity Patent Rights, and to Licensor’s knowledge, the Licensed Reprise Patent Rights and Licensed CPEX Patent Rights have been filed; 

 

(h) none of the Licensed Serenity Patent Rights, the Licensed Serenity Know-How and, to Licensor’s knowledge, none of the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights were developed with funding from any Governmental Authority such that any Governmental Authority has any march in rights or other rights to use the Licensed Serenity Patent Rights, the License Serenity Know-How, the Licensed Reprise Patent Rights, or the Licensed CPEX Patent Rights; 

 

(i) to Licensor’s knowledge, no Third Party has infringed or misappropriated any of the Licensed Rights or the Sublicensed Rights; 

 

(j) all inventors of any inventions included within the Licensed Serenity Patent Rights and, to the knowledge of Licensor, the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights have assigned their entire right, title, and interest in and to such inventions and the corresponding patents and patent applications to Licensor, Reprise, or CPEX, as applicable, and have been listed as inventors in the Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent Rights, as applicable; 

 

(k) no agreements that Licensor or its Affiliates may have with any Third Party provide such Third Party with any rights of first offer, rights of first refusal, or any other rights to make, have made, use, conduct Clinical Studies for, sell, offer for sale, have sold, import, export, or otherwise Exploit the Product in the Field in the Territory or the right to use the Licensed Rights or the Sublicensed Rights in connection with the Exploitation of the Product in the Field in the Territory; and Licensor has received no notice from a Third Party of any suit, action, proceeding, or arbitration pending or threatened against it that the proposed terms and conditions of this Agreement, and the Parties’ performance in accordance therewith, do or shall conflict or interfere with in a manner resulting in a breach or default under, or other violation of, any agreements that Licensor or its Affiliates may have with any Third Party; 

 

to Licensor’s knowledge, (i) each of the CPEX License Agreement and the Reprise License Agreement is valid and enforceable in accordance with its terms, is in full force and effect, and there are no approvals or consents required to make it effective, (ii) Licensor has supplied Licensee with a true and correct copy of the CPEX License Agreement and the Reprise License Agreement , together with all amendments, waivers, or other changes thereto, (iii) Licensor has performed all material obligations required to be performed by it in connection with the CPEX License Agreement and the Reprise License Agreement, (iv) Licensor shall not materially breach and is not in material breach of the CPEX License Agreement or the Reprise License Agreement, (v) Licensor is not in receipt of any claim of default, cure notice, or show cause notice under the CPEX License Agreement or the Reprise License Agreement, and (vi) there is no current material breach or anticipated material breach by any other party to the CPEX License Agreement or the Reprise License Agreement; 

 

(m)

 (i) Licensor is the named sponsor of the First Approved NDA for the Product; and (ii) with respect to all Regulatory Documentation to obtain Regulatory Approvals for the Product in the Field: (A) the data, information and/or all other documents in Licensor’s or its Affiliates submissions were, are and shall be free from fraud or material falsity, and neither Licensor nor its Affiliates has made any material misrepresentation or omission in connection with such data; (B) the Regulatory Approvals have not been and will not be obtained either through bribery or the payment of illegal gratuities by Licensor; (C) the data, information and/or all other documents in Licensor’s or its Affiliates’ submissions are, were and shall be accurate and reliable for purposes of supporting approval of the submissions; and (D) the Regulatory Approvals shall be obtained without illegal or unethical behavior of any kind by Licensor or its Affiliates; provided that Licensor shall not be deemed to be in breach of this Section 10.2(m) if the violation of this Section 10.2(m) results from the action or omission of Licensee of Licensee’s Affiliates, Sublicensees, or contractors (other than Licensor); 

 

(n) Licensor believes in good faith, based on the information set forth in Schedule 10.2(n), that FDA will consider amending or supplementing the First Approved NDA (or the related IND) in the manner described in Schedule 10.2(n); provided, however, that Licensor cannot assure that FDA will approve such amendment or supplement. 

 

(o) except as expressly permitted hereunder, Licensor agrees not to, and agrees to cause its Affiliates and Sublicensees not to (i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, or (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse or other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product; and

 

(p) other than the CPEX License Agreement, the Reprise License Agreement, the Renaissance Supply Agreements, and the other Third Party Supply Agreements, Licensor and/or its Affiliates have not entered into any agreements with any Third Party, pursuant to which any Third Party has granted to Licensor, or Licensor has granted to any Third Party, any rights to licenses to, in or under any of the Licensed Rights or the Sublicensed Rights or other intellectual property rights that relate to the Product, or relating to the manufacture of the Product.

 

10.3 Additional Representations, Warranties, and Covenants of Licensee. Licensee hereby represents, warrants, and covenants to Licensor, as of the Effective Date and except as otherwise stated in Schedule 10.3, that: 

 

(a) if, during the term of this Agreement Licensee has reason to believe that it or any of its employees, officers, subcontractors, or consultants rendering services relating to the Product: (i) is or will be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or will be under indictment under said Section 335a, then Licensee shall immediately notify Licensor in writing; 

 

 (b) as of the Effective Date, there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any nature, judgment, decree, decision, injunction, writ, or order pending or, to the knowledge of Licensee’s senior management, threatened by, against Licensee regarding this Agreement, whether at law or in equity, before or by any Third Party; and Licensee shall provide notice of any of the foregoing to the extent it affects Licensee’s performance of its obligations under this Agreement; 

 

(c) except for information provided by Licensor, its Affiliates or Sublicensees: (i) the data and information in Licensee’s submissions and modifications of Regulatory Documentation relating to the Product shall be free from fraud or material falsity; (ii) Regulatory Approvals for the Product hereafter obtained will not be obtained either through bribery or the payment of illegal gratuities by Licensee; (iii) the data and information in Licensee’s submissions and modifications of any Regulatory Documentation shall be accurate and reliable; and (iv) any such the Regulatory Approvals will be obtained without illegal or unethical behavior of any kind by Licensee; provided that Licensee shall not be deemed to be in breach of this Section 10.3(c) if the violation of this Section 10.3(c) results from the action or omission of Licensor or its Affiliates, Sublicensees (other than Licensee), or contractors; and

 

(d) except as expressly permitted hereunder, Licensee agrees not to, and agrees to cause its Affiliates and Sublicensees not to (i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse or other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, or (iv) bring any action or proceeding or otherwise assert any claim under any Applicable Law in the event any licensee (or sublicensee or any entity or person acting on its behalf) initiates any proceeding or otherwise assert any claim in any court, administrative agency, or other forum with jurisdiction over such proceeding or claim, that any of the Licensed Rights or Sublicensed Rights are invalid, unenforceable, or not infringed, violated, or misappropriated. In the event that Licensee or any Affiliate or Sublicensee of Licensee initiates any proceeding or otherwise asserts any claim in violation of clause (iv) of this Section 10.3, and the result thereof is a final decision, ruling, holding, award, or other disposition to the effect that any of the Licensed Rights or Sublicensed Rights are valid, enforceable, or infringed, violated, or misappropriated, then each of the royalty rates set forth in the table in Section 8.3(a) will each be increased by [***] and the party initiating such proceeding or otherwise asserting such claim shall pay the attorneys’ fees and expenses incurred by Licensor in defending against such proceeding or claim.

 

10.4 Inaccuracies. Without limiting either Party’s rights and remedies at law, in equity or under this Agreement, if, at any point in time (not just at the times when the warranties are deemed granted), either Party becomes aware of any inaccuracies in the foregoing warranties and representations, such Party shall promptly notify the other Party of such inaccuracies, with a detailed written explanation.

 

KASAN_기술이전, 특허 라이선스 계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTI

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019. 5. 20. 16:19
Trackback 0 : Comment 0

댓글을 달아 주세요


 

-- 기술사용계약의 적용범위 해석 + 계약대상 특허기술 범위 + 계약위반 책임여부 판단: 서울고등법원 2016. 3. 31. 선고 20152055753 판결 --

 

1.    분쟁대상 계약 및 쟁점

 

특허권 보유자이고, 계약 당시 계열사 명의 특허출원 중이었던 원고 회사와 시공전문 피고회사는 다음과 같은 기술사용계약을 체결하였습니다. 그런데, 그 내용이 통상의 기술이전이나 실시권 설정 계약과는 많이 달라 계약위반 여부에 관한 분쟁이 발생한 것입니다.

 

원고 회사는 2013. 4.경 피고와 사이에 원고가 피고에게 원고가 보유한 특허 및 그 외 일반 포장재류를 포함한 사급판매제품 및 조달청 등록판매제품에 관한 모든 기술에 대하여 그 사용을 허락하고, 원고가 피고의 필요시 피고에게 통상실시권을 즉시 등록해주기로 하는 것 등을 내용으로 하는 기술사용계약을 체결하면서 다음과 같이 약정하였습니다.

 

1. 사용기간: 계약일로부터 3년으로 하며 정산 기일은 매 건별 정산하여 피고가 수금 후 10일 이내에 원고에게 지급한다.

1-2. 기술사용료는 매출액 전체에 대하여 아래의 지급율에 따라서 지급한다.

 

           구분

내용

기술사용료

지급율

1

원고가 영업을 하여 피고를 통하여 계약을

할 경우

원고는 피고에게 법인 사용에 대한 비용으로 지급율에 의해 지급한다.

5%

(세금포함)

2

피고가 영업과 시공을 동시에 수행 경우

피고는 원고에게 기술사용료를 지급율에 의해 지급한다.

, 기설계된 현장 제외하며 신규설계 및 진행건에 한함[P현장, Q하류, R지구(수자원공사) 현장제외].

10%

(VAT별도)

4항의 보수재 2종을 사용한 공사 건에 대해서는 이미 기술료가 포함된 단가로 제품을 공급받으므로 별도의 기술료를 피고가 원고에게 지급하지 않아도 된다.

0%

(VAT별도)

 

2. 상호 협의되지 않은 일방적인 계약, 납품 진행, 3의 사업자를 이용한 영업행위 또는 계약행위는 특허 침해 및 계약 위반으로 공사대금의 2배를 손해배상하여야 한다.

3. 모든 공사에 필요한 재료는 원고에게 별도로 구매하여 시공 납품하여야 하며 시중에 구매되는 물품은 별도로 구매하고 단가는 일반시중가보다 저렴하게 공급한다.

4. 제품공급단가표

 

품명

단위(규격)

단가

비고

투수기층첨가제/개질재

10Kg(포대)

*

 

자연토바인더

Kg

*

 

자연토

25Kg(포대)

*

 

콘크리트/아스콘용보수재

25Kg()

*

골재포함(set)

미세줄눈보수재

18(EA)

*

 

컬러바인더

적색/녹색 18()

 

 

 

 

1.    독자적 공사수주, 시공 및 계약 분쟁

 

피고회사는 원고회사와 협의 없이 공사를 수주하고 제3자로부터 미세줄눈보수재 명목으로 납품받은 열경화성 수지를 이용하여 공사를 시행하였습니다.

 

이에 원고회사는 위 기술사용계약 제4조에 표시된 공급제품에 ‘미세줄눈보수재’가 포함되어 있고, 원고와 혐의 없이 ‘미세줄눈보수재’를 납품받아 사용한 것은 특허발명의 기술로서 계약의 적용대상에 포함되고, 계약 제2조를 위반하였다고 주장합니다. 따라서, 계약 제2조에 따른 손해배상으로 공사금액의 2배 상당액을 청구한 것입니다.

 

2.    서울고등법원 판결

 

가.  계약 적용범위 한정해석 

 

"계약서의 제목이 ‘기술사용계약서’이고, ‘통상실시권의 즉시 등록’이나 ‘기술사용료의 지급’과 관련한 자세한 내용이 포함되어 있는 사정에 비추어 보면, 이 사건 계약은 기본적으로 원고가 보유하고 있는 특허에 관한 이용허락계약의 성질을 갖는다고 보인다.

 

비록 계약서에 공급하는 제품에 대한 단가표에 ‘콘크리트/아스콘용 보수재’와 ‘미세줄눈보수재’가 포함되어 있으나, 이는 당시 피고가 모든 공사에 필요한 재료는 원고로부터 별도로 구매하여 시공 납품하기로 한 약정(3)에 따라 원고가 피고에게 납품하기로 한 원자재의 항목, 규격 및 납품단가 등을 규정한 것에 불과한 것으로 보인다."

 

나.  특허출원 단계 기술내용 포함여부

 

"이 사건 계약 당시 작성된 계약서에는 이 사건 계약이 적용되는 기술 중 특허와 관련된 부분에 대하여 ‘원고 보유 특허’라고만 기재되어 있을 뿐이고, 원고가 이 사건 계약 당시 특허출원 중인 발명이나 향후 보유하게 될 특허권의 발명에 관한 기술도 이 사건 계약의 적용대상에 포함된다는 취지의 내용이 전혀 포함되어 있지 않을 뿐만 아니라, 이 사건 계약 당시 원고가 피고에게 원고 측이 특허출원한 이 사건 특허발명과 관련하여 이 사건 특허발명의 구체적 내용을 알 수 있는 특허출원서나 특허명세서를 제시하는 등으로 이 사건 특허발명에 관하여 설명하고, 이 사건 특허발명에 관한 기술도 이 사건의 계약의 적용대상에 포함시키기로 하는 논의가 있었다고 볼 만한 특별한 사정이 없다.

 

계약 당시 원고는 피고의 필요시 ‘통상실시권’을 ‘즉시’ 등록해주기로 약정하였는데, 특허권은 설정등록에 의하여 발생하고(특허법 제87조 제1), 특허권자는 그 특허권에 대하여 타인에게 통상실시권을 허락할 수 있으며(특허법 제101조 제1), 통상실시권을 등록한 경우에는 그 등록 후에 특허권 또는 전용실시권을 취득한 자에 대해서도 그 효력이 발생하므로(특허법 제118조 제1), 특허등록이 되지 않은 발명이나 기술 또는 특허출원 중인 발명에 대해서 피고의 필요에 따라 원고가 즉시 통상실시권을 설정해 줄 수 는 없는 점 등에 비추어, 이는 이 사건 계약을 통하여 원고가 피고에게 이용허락을 한 대상이 특허권에 한정됨을 전제로 한 것으로 보인다.

 

이 사건 계약 제2조는 피고가 원고에게 매주 신규 영업현황을 서면으로 보고하고, 신규 계약 및 진행을 원고와 협의 후에 진행하여야 하며, 상호 협의되지 않은 일방적인 계약, 납품 진행, 2의 사업자를 이용한 영업행위 또는 계약행위는 계약 위반일 뿐 아니라 ‘특허 침해’라고 하고 규정하고 있는데, 이러한 조항도 이 사건 계약을 통하여 원고가 피고에게 이용허락을 한 대상이 등록된 특허권에 한정됨을 전제로 해야만 합리적인 설명이 가능해 보인다.

 

이 사건 계약의 적용대상 기술은 이 사건 계약 체결 당시 원고가 보유하고 있는 특허권에 관한 기술에 한정된다고 해석하는 것이 사회통념에 비추어 합리적이고, 당사자의 통상적인 의사에도 맞다."

 

다.  계약위반 불인정

 

피고회사가 이 사건 공사를 시행하면서 원고의 허락 없이 제3자로부터 미세줄눈보수재 명목으로 납품받은 열경화성 수지 제품을 이용하였지만 서울고등법원은 계약서 제2조에 해당하지 않는다고 판단하였습니다.

 

계약서 제2조의 "특허침해 및 계약위반"이란 문언을 다음과 같이 제한 해석한 것입니다. "앞서 본 대로 이 사건 계약의 적용대상인 기술 등에 이 사건 계약 당시 원고 측이 특허출원 중이던 이 사건 특허발명에 관한 기술이나 ‘콘크리트/아스콘보수재’ 또는 ‘미세줄눈보수재’ 또는 ‘미세줄눈보수재’ 그 자체가 포함된다고 볼 수 없는 이상, 이와 다른 전제에 선 원고의 주장은 나아가 볼 필요 없이 이유 없다."

 

라.  불명확한 계약의 해석에 관한 법리

 

"계약은 복수 당사자의 의사표시 합치로 성립하는 법률행위로서 계약의 해석은 그 계약의 의미 내용을 확정하는 작업이므로 당사자의 공통된 의사가 인정되지 아니하여 표시의 객관적 의미를 확정하여야 하는 경우에 계약당사자 사이에 어떠한 계약 내용을 처분문서인 서면으로 작성한 경우에 문언의 객관적인 의미가 명확한 때에는 특별한 사정이 없다면 문언대로의 의사표시의 존재와 내용을 인정하여야 하고,

 

그 문언의 객관적인 의미가 명확하게 드러나지 아니하여 당사자 사이에 계약의 해석을 둘러싸고 이견이 있어 처분문서에 나타나 당사자의 의사해석이 문제가 되는 경우에는 그 문언의 내용과 계약이 이루어지게 된 동기와 경위, 당사자가 계약으로 달성하려고 하는 목적과 진정한 의사, 거래의 관행 등을 종합적으로 고찰하여 사회정의와 형평의 이념에 맞도록 논리와 경험의 법칙, 그리고 사회 일반의 상식과 거래의 통념에 따라 계약 내용을 합리적으로 해석하여야 한다(대법원 2011. 5. 13. 선고 201058728 판결)."

 

첨부: 서울고등법원 2016. 3. 31. 선고 20152055753 판결

  서울고등법원 2015나2055753 판결.pdf

 

 

작성일시 : 2016. 4. 27. 13:12
Trackback 0 : Comment 0

댓글을 달아 주세요


-- 인터넷뱅킹 등에 사용되는 보안소프트웨어 플러그인 통합설치 프로그램 관련 영업비밀 침해 사건 서울중앙지방법원 2016. 1. 15. 선고 2014가합563704 판결 --

 

1. 당사자

 

X회사는 2008. 3.경부터 베라포트라는 MS사의 인터넷 익스플로러(IE) 웹브라우저에 사용되는 액티브엑스(ActiveX) 통합설치 프로그램을 개발하여 2009. 5. 은행 등에 공급하였고, 2010. 8.경부터는 MS IE 이외의 웹브라우저들에서 동일한 보안기능을 수행할 있는 베라인 프로그림을 개발하여 사업제휴를 맺은 Y회사를 통하여 판매하였습니다.

 

베라포트는 MS윈도우 운영체제의 IE 웹브라우저에서만 동작하지만, 베라인은 멀티 웹브라우저에선 각종 ActiveX 컨트롤 프로그램을 통합 설치할 있습니다.

 

2. X회사와 Y회사 간의 사업제휴 계약의 체결

 

X회사는 2009. 9. 9. Y회사와, X회사가 Y회사에게 통합 ActiveX 관리 모듈인 베라포트 프로그램을 대금 35,000,000원에 공급한다는 물품공급계약을 체결하였습니다. X회사는 2010. 3. 1. Y회사와, X회사와 Y회사가 멀티 브라우저 지원 솔루션 사업에서 상호협력하기로 하는 내용의 사건 사업제휴계약을 체결하였습니다. 주요 계약 규정은 아래와 같고, 갑은 Y회사, 을은 X회사입니다.

2 (용어의 정의)

1 멀티 브라우저 지원 솔류션이라 함은 Windows 기반의 PC에서 Internet Explorer에서만 제공되는 인터넷 서비스에 대하여 FireFox, Chrome, Safari, Opera에서 인터넷 서비스를 이용할 있게 주는 플러그인 솔루션이다.

2 VeraIN 또는 베라인은 을이 개발하고 구축, 유지관리하는 멀티 브라우저 지원 솔루션이다.

3 (역할 책임)

1 갑은 베라인의 사업 활성화를 위한 영업 마케팅 업무를 담당한다.

2 을은 베라인 사업 활성화를 위한 베라인의 개발, 구축, 유지관리 업무를 담당한다.

4 을은 베라인에서 현재 지원하는 브라우저/OS 외에 브라우저 OS 지원에 적극 협력한다.

10 (기밀의 유지)

1 양사는 협약서를 기준으로 발생된 신규(기존)사업에 대한 비밀유지의 책임을 지며, 협약이 종료된 시점으로부터 3년간 기밀유지에 대한 책임이 있다.

2 항의 책임을 이행하지 않은 당사자는 상대방에게 손해배상의 의무를 가지며, 경우 피해를 입은 상대방의 의견을 최대한 존중하여 배상내용을 정한다.

 

협력 과정에서 X회사는 2010. 2. 24.경부터 2010. 9. 29.경까지 Y회사에게 많은 자료(이하 ' 사건 자료') 이메일 등을 통하여 차례에 걸쳐 제공하였습니다.

 

3. Y회사의 SWIFT 프로그램 개발

 

Y회사는 2012. 2. 경부터 X회사 프로그램과 동일한 기능을 수행하는 통합 설치 프로그램인 SWIFT 프로그램의 개발에 착수하여 2012. 6-8.경에 위도우 버전을 개발하였습니다. Y회사는 2012. 8. 회사 홈페이지에 프로그램의 소개 자료를 게재하였다가 X회사가 2012. 8. 22. 이의를 제기하자 2012. 8. 27. 삭제하였습니다. 그리고 Y회사는 2013. 1.경부터 다시 프로그램을 소개하면서 영업활동을 계속하고 있습니다.

 

또한 Y회사는 2012. 10. 10. Z회사로부터 액티브엑스 컨트롤 설치 방법에 관한 특허의 통상실시권을 설정받고 대가를 지급하는 실시권 설정계약을 체결하였습니다. 실시특허는 통합 인스톨러 액티브엑스 컨트롤을 사용자 클라이언트(PC) 설치함으로써 동일한 서비스 제공자가 제공하는 웹페이지들의 액티브엑스 컨트롤들을 보안경고 메시지 없이 한꺼번에 설치할 있는 방법에 관한 발명에 관한 것입니다.

 

4. X회사의 사건 자료에 대한 영업비밀의 성립 여부

 

법원은 사건 자료에 대하여 비공지성, 경제적 유용성, 비밀관리성을 인정하여 부정경쟁방지법 2 2호의 영업비밀에 해당함을 인정하였습니다. 통상 중소기업의 영업비밀 분쟁에서 문제가 되는 것은 상당한 노력에 의해 비밀로 유지되었는지 여부인 비밀관리성에 대한 것입니다. 사안에서는 X회사의 소프트웨어에 대한 비밀관리성에 관하여 다음과 같은 사유로 인정하였으니, 관련 소프트웨어 중소기업들은 업무에 참고하시길 바랍니다.

 

(1) 설립 초기부터 개발 프로그램과 관련된 수정사항 등을 wiki 또는 jira 등의 내부정보 소스 관리 시스템에 등록하여 관리하였고, 프로그램 개발에 관한 자료가 저장되어 있는 프로젝트 서버는 시건장치가 되어 있는 별도의 공간에 배치되어 있어 권한을 가진 소수의 사람만이 물리적으로 접근할 있다.

(2) 영업비밀의 유출을 방지하기 위하여 종업원들에게 입퇴사시에 비밀유지서약서 등을 징구하고 있다.

(3) Y회사와 사건 사업제휴계약 체결 시에도 비밀유지조항을 추가하여 업무 관계에 있는 타회사에도 비밀유지의무를 부과하였다.

(4) 이메일을 통하여 사건 자료를 첨부하여 제공하면서 이메일에 '첨부 자료가 개발의 핵심 부분을 담고 있어 대외적으로 비공개하여야 한다'라는 취지의 기재 또는 'Confidential'이라고 표시하였다.

 

5. 법원의 판단 - 영업비밀 침해 불인정

 

그러나 법원은 다음과 같은 사정으로 Y회사가 X회사의 영업비밀을 침해한 것으로 수는 없다고 판단하였습니다.

 

(1) Z회사의 특허도 컴퓨터 웹페이지 프로그램 구동에 필요한 액티브엑스 컨트롤을 통합적으로 설치하는 방법에 관한 것이고, Y회사가 특허를 사용하는 프로그램 개발 후에 본격적인 판매를 위하여 실시계약을 체결할 수도 있는 것이며, 실시 계약에 실시료 금액, 특허표시, 기밀유지 등의 사항이 구체적으로 기재되어 있다는 사정을 인정하여 Y회사가 X회사의 영업비밀에 대한 침해를 감추기 위하여 형식적으로 Z회사와 실시계약을 체결하였다고 보기는 어렵다고 보았습니다.

 

(2) 한국저작권위원회의 감정에 의하면 20 감정사항 중에서 불과 9 항목만이 공통적으로 존재하고, 사실조회 결과 소프트웨어 설계시 고객의 요구사항을 받아 프로세스와 데이터를 나누어 분석 설계하고 추후 이를 비교 검토하여 설계를 완성하는 과정에 산출되는 데이터 분석 결과 하나인 테이블정의서의 경우 서로 유사성이 전혀 없었으며, 공통요소가 프로그램의 수행에 절대적인 요소이거나 사건 자료로부터 추출된 것임을 인정할 증거가 없다는 사정이 인정되어 Y회사가 사건 자료를 이용하여 X회사의 베라인 프로그램의 기능과 구조가 동일유사한 Y회사의 프로그램을 개발한 것으로 수는 없다고 판단하였습니다.

 

결론적으로 법원은 위와 같은 이유로 Y회사가 X회사가 제공한 사건 자료를 무단으로 사용하여 Y회사 프로그램을 제조 판매하였다는 등의 영업비밀 침해를 인정할 수는 없다고 판단한 것입니다.

 

첨부 : 서울중앙지방법원 2016. 1. 15. 선고 2014가합563704 판결문

  261-서울중앙 2014가합563704_판결문_검수완료.pdf 

 

정회목 변호사

작성일시 : 2016. 2. 25. 09:30
Trackback 0 : Comment 0

댓글을 달아 주세요